The KRAS proto-oncogene plays a key role in tumor cell growth, proliferation, survival, and invasion, with mutations detected in more than 90 % of PDAC.43–45 Thus, mutant KRAS antigens are promising immunotherapy targets for many malignancies.46 The ELI-002 vaccine combines lipid-conjugated mutant KRAS-derived peptides, G12D, and G12R with a lipid-conjugated immune-stimulatory oligonucleotide. The gene discussed is KRAS; the disease is neoplasm.